Effect of botulinum neurotoxin treatment in the lateral spread monitoring of microvascular decompression for hemifacial spasm
Corresponding Author
Miguel E. Habeych MD, MPH
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USASearch for more papers by this authorAalap C. Shah BS
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Search for more papers by this authorTara N. Nikonow BS
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Search for more papers by this authorJeffrey R. Balzer PhD
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Department of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Search for more papers by this authorDonald J. Crammond PhD
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Search for more papers by this authorParthasarathy D. Thirumala MD, MS
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Search for more papers by this authorAmin Kassam MD
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Search for more papers by this authorMichael Horowitz MD
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Department of Radiology, University of Pittsburgh, Pittsburgh, Pennyslvania, USA
Search for more papers by this authorCorresponding Author
Miguel E. Habeych MD, MPH
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USASearch for more papers by this authorAalap C. Shah BS
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Search for more papers by this authorTara N. Nikonow BS
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Search for more papers by this authorJeffrey R. Balzer PhD
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Department of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Search for more papers by this authorDonald J. Crammond PhD
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Search for more papers by this authorParthasarathy D. Thirumala MD, MS
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Search for more papers by this authorAmin Kassam MD
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Search for more papers by this authorMichael Horowitz MD
Center for Clinical Neurophysiology Department Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA
Department of Radiology, University of Pittsburgh, Pittsburgh, Pennyslvania, USA
Search for more papers by this authorAbstract
Introduction: Botulinum neurotoxin (BtNtx) treatment for hemifacial spasm (HFS) prior to microvascular decompression (MVD) is hypothesized to be a factor in the variability of intraoperative neurophysiological monitoring (IONM) during this procedure. Methods: We analyzed 282 MVDs performed at the University of Pittsburgh Medical Center between January 1, 2000 and December 31, 2007. We retrospectively compared the lateral spread response (LSR) in the mentalis muscle when stimulus-triggered electromyography (EMG) was elicited from the facial nerve. Previous BtNtx treatment was the grouping factor. Results: Baseline LSR amplitudes during MVD (prior BtNtx: mean = 341.47 μV; no BtNtx: mean = 241.81 μV) were significantly different between groups (df = 1,281; t = −2.463; P = 0.014). Comparisons of latency and current threshold at baseline, as well as HFS disappearance or LSR persistence after the procedure, did not achieve statistical significance. Conclusions: HFS patients treated with BtNtx prior to MVD demonstrated higher LSR baseline amplitudes during IONM. This could be related to muscle poly-reinnervation after recovery from repeated BtNtx use. Muscle Nerve, 2011
REFERENCES
- 1 Lew MF. Review of the FDA-approved uses of botulinum toxins, including some data suggesting efficacy in pain reduction. Clin J Pain 2002; 18( suppl 6): S142–S146.
- 2 Papapetropoulos S, Singer C. Botulinum toxin in movement disorders. Sem Neurol 27: 183–194.
- 3 Comella CL, Pullman SL. Botulinum toxins in neurological disease. Muscle Nerve 2004; 29: 628–644.
- 4 Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1707–1714.
- 5 Duchen LW. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibers of the mouse J Neurol Sci 1971; 14: 47–60.
- 6 Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve 1994; 17: 1385–1392.
- 7 Holland RL, Brown MC. Nerve growth in the botulinum toxin poisoned muscle. Neuroscience 1981; 6: 1167–1179.
- 8 De-Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 96: 3200–3205.
- 9
Wang A,
Jankovic J.
Hemifacial spasm: clinical findings and treatment.
Muscle Nerve
1998;
12:
1740–1747.
10.1002/(SICI)1097-4598(199812)21:12<1740::AID-MUS17>3.0.CO;2-V Google Scholar
- 10 Girard N, Poncet M, Caces F, Tallon Y, Chays A, Martin-Bouyer P, et al. Three dimensional MRI of hemifacial spasm with surgical correlation. Neuroradiology 1997; 39: 41–45.
- 11 Tan EK, Chan LL. Clinico-radiologic correlation in unilateral and bilateral hemifacial spasm. J Neurol Sci 2004; 222: 59–64.
- 12 Boghen DR, Lesser RL. Blepharospasm and hemifacial spasm. Curr Treat Options Neurol 2000; 2: 393–400.
- 13 Kemp LW, Reich SG. Hemifacial spasm. Curr Treat Options Neurol 2004; 6: 175–179.
- 14 Gardner WJ, Sava GA. Hemifacial spasm, a reversible pathophysiologic state. J Neurosurg 1962; 19: 240–247.
- 15 Jannetta PJ, Abbassy M, Maroon JC, Ramos FM, Albin MS. Etiology and definitive microsurgical treatment of hemifacial spasm: operative techniques and results in 47 patients. J Neurosurg 1977; 47: 321–328.
- 16 Elston JS. Botulinum toxin treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry 1986; 49: 827–829.
- 17 Mauriello J. Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin. Neurology 1985; 35: 1499–1500.
- 18 Dodel RC, Kirchner A, Koehne-Volland R, Kunig G, Ceballos-Baumann A, Nauman M, et al. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics 1997; 12: 695–706.
- 19 De-Fazio G, Abbruzzese G, Girlanda P, Vacca L, Currá A, De Salvia R, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10 year multicenter study. Arch Neurol 2002; 59: 418–420.
- 20 Ryoong H, Han IB, Moon JY, Chang JW, Chung SS. Microvascular decompression for hemifacial spasm: analysis of operative complications in 1582 consecutive patients. Surg Neurol 2008; 69: 153–157.
- 21 Mejia NI, Vuong KD, Jankovic J. Long term botulinum toxin efficacy, safety and immunogenicity. Mov Disord 2005; 20: 592–597.
- 22 Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/Neuroblock. Eur J Neurol 2006; 13( suppl 1): 11–15.
- 23 Dae-yul K, Byung-mo O, Nam-jong P. Central effects of botulinum toxin type A in humans. Int J Neurosci 2006; 116: 667–680.
- 24 Lange DI, Brin MF, Warner CI, Fahn S, Lovelace RE. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987; 10: 552–555.
- 25 Kuehn BM. FDA requires black box warnings on labeling for botulinum toxin products. JAMA 2009; 301: 2316.
- 26 Kalkanis SN, Eskandar EM, Carter BS, Barker FG II. Microvascular decompression surgery in the United States, 1996–2000. Mortality rates, morbidity rates, and the effects of hospital and surgeons volumes. Neurosurgery 2003; 52: 1251–1262.
- 27 Nielsen VK. Pathophysiology of hemifacial spasm: II. Lateral spread of the supraorbital nerve reflex. Neurology 1984; 34: 427–431.
- 28 Frick CG, Richtsfeld M, Sahani ND, Kaneki M, Blobner M, Jevendra-Martyn JA. Long term effects of botulinum toxin on neuromuscular function. Anesthesiology 2007; 106: 1139–1146.
- 29 Harper CM. AAEM case report #21: Hemifacial spasm: preoperative diagnosis and intraoperative management. Muscle Nerve 1991; 14: 213–218.
- 30 Møller AR, Jannetta PJ. Monitoring facial EMG responses during microvascular decompression operations for hemifacial spasm. J Neurosurg 1987; 66: 681–685.
- 31 Nielsen VK. Electrophysiology of the facial nerve in hemifacial spasm: ectopic/ephaptic excitation. Muscle Nerve 1985; 8: 545–555.
- 32 Sanders DB. Ephaptic transmission in hemifacial spasm: a single fiber EMG study. Muscle Nerve 1989; 12: 690–694.
- 33 Black JD, Dolly O. Interaction of 125-I labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 1986; 103: 521–534.
- 34 Catsicas S, Grenningloh G, Pich EM. Nerve terminal proteins: to fuse to learn. Trends Neurosci 1994; 17: 368–373.
- 35 Montecucco C, Schiavo G, Rossetto O. The mechanism of action of tetanus and botulinum neurotoxins. Arch Toxicol 1996; 18( suppl): 342–354.
- 36 Bogucki A. Serial SFEMG studies of orbicularis oculi muscle after the first administration of botulinum toxin. Eur J Neurol 1999; 6: 461–467.
- 37 Glocker FX, Guschlbauer B, Lucking CH, Deuschl G. Effects of local injections of botulinum toxin on electrophysiological parameters in patients with hemifacial spasm: role of synaptic activity and size of motor units. Neurosci Lett 1995; 187: 161–164.
- 38 Eleopra R, Tugnoli V, Quatrale R, Gastaldo E, Rosetto O, De Grandis D, et al. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting. Clin Neurophysiol 2002; 113: 1258–1264.
- 39 Sonoo M, Stålberg E. The ability of MUP parameters to discriminate between normal and neurogenic MUPs in concentric EMG: analysis of the MUP “thickness” and the proposal of a “size index.” Electroencephalogr Clin Neurophysiol 1993; 89: 291–303.
- 40 Stålberg E, Sonoo M. Assessment of variability in the shape of the motor unit action potential, the “jiggle,” at consecutive discharges. Muscle Nerve 1994; 17: 1135–1144.
- 41 Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004; 15: 615–625.
Citing Literature
